Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease.
- Published In:
- Investigative ophthalmology & visual science, 55(8), 5401-9 (2014)
- Authors:
- Vijmasi, Trinka, Chen, Feeling Y T, Balasubbu, Suganthalakshmi, Gallup, Marianne, McKown, Robert L, Laurie, Gordon W, McNamara, Nancy A
- Database ID:
- RPEP-02533
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02533APA
Vijmasi, Trinka; Chen, Feeling Y T; Balasubbu, Suganthalakshmi; Gallup, Marianne; McKown, Robert L; Laurie, Gordon W; McNamara, Nancy A. (2014). Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease.. Investigative ophthalmology & visual science, 55(8), 5401-9. https://doi.org/10.1167/iovs.14-13924
MLA
Vijmasi, Trinka, et al. "Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease.." Investigative ophthalmology & visual science, 2014. https://doi.org/10.1167/iovs.14-13924
RethinkPeptides
RethinkPeptides Research Database. "Topical administration of lacritin is a novel therapy for aq..." RPEP-02533. Retrieved from https://rethinkpeptides.com/research/vijmasi-2014-topical-administration-of-lacritin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.